Clinical Trial Update: BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects

View source ↗

Summary

A completed follow-up study (BS-FU01) of FluBHPVE6E7 conducted by BlueSky Immunotherapies GmbH, focusing on safety issues related to HPV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• FluBHPVE6E7

Snippet

Sponsor: BlueSky Immunotherapies GmbH | Conditions: Safety Issues, HPV Infection | Status: COMPLETED